Cardiff Oncology, Inc. - Common Stock (CRDF)

Historical Holders from Q2 2020 to Q3 2025

Symbol
CRDF on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
66,577,393
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
25,150,264
Holdings value
$51,811,088
% of all portfolios
0%
Number of holders
109
Number of buys
48
Number of sells
-49
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cardiff Oncology, Inc. - Common Stock (CRDF)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 5.8% +37.5% $10,678,250 +$2,780,523 3,841,097 +35.2% BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 5.6% $11,744,252 3,728,334 The Vanguard Group 30 Jun 2025
PFIZER INC 3.6% $6,704,178 2,411,575 Pfizer Inc. 13-5315170 31 Dec 2024

Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 25,150,264 $51,811,088 -$9,699,936 $2.06 109
2025 Q2 28,660,334 $90,269,224 -$11,262,615 $3.15 114
2025 Q1 32,345,011 $101,559,895 +$10,196,300 $3.14 116
2024 Q4 28,092,578 $121,918,732 +$50,159,924 $4.34 117
2024 Q3 12,761,449 $34,074,638 -$895,795 $2.67 82
2024 Q2 13,089,737 $29,054,064 +$5,567,075 $2.22 90
2024 Q1 8,576,486 $45,797,587 +$17,940,647 $5.34 74
2023 Q4 5,309,425 $7,858,363 -$215,046 $1.48 55
2023 Q3 5,456,265 $7,583,910 -$756,925 $1.39 55
2023 Q2 5,991,988 $8,808,700 -$1,673,969 $1.47 50
2023 Q1 7,049,719 $11,633,255 -$748,502 $1.65 52
2022 Q4 7,699,341 $10,776,288 -$189,952 $1.4 55
2022 Q3 7,924,242 $12,205,032 -$1,956,121 $1.54 47
2022 Q2 8,925,020 $19,636,792 -$17,827,128 $2.2 54
2022 Q1 16,524,301 $40,953,207 -$30,166,620 $2.48 81
2021 Q4 22,015,576 $132,083,136 +$5,192,808 $6.01 81
2021 Q3 21,121,086 $140,722,888 -$35,953,961 $6.66 82
2021 Q2 26,525,986 $176,397,333 +$10,825,969 $6.65 81
2021 Q1 24,079,194 $222,960,463 -$69,848,932 $9.26 70
2020 Q4 26,636,620 $479,141,900 +$144,188,615 $17.99 79
2020 Q3 18,710,542 $265,500,071 +$207,902,213 $14.19 63
2020 Q2 4,923,525 $24,668,025 +$24,668,026 $5.01 23